The Business Journals

Mass. battery startup to go public via SPAC deal at $1.1B valuation

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Billerica battery startup ...
来自MSN

Cartesian Growth III to take Factorial public via merger

Cartesian Growth Corp. III Class A ( (CGCT)) just unveiled an announcement. On December 17, 2025, Cartesian Growth Corporation III and Factorial Inc. signed a definitive business combination agreement ...
The New York Times

Massachusetts Battery Start-Up to List on Stock Exchange

Factorial, the start-up, said the listing would provide money that would help it bring new solid-state batteries to market as soon as 2027. By Jack Ewing Factorial Energy, which is developing advanced ...
Seeking Alpha

Recursion jumps as J.P. Morgan upgrades on lead program

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
The Boston Globe

Battery maker Factorial has left its Methuen factory. Another Mass. company will move in.

Two years ago, Factorial Energy opened its battery-making plant in Methuen to much fanfare, drawing Governor Maura Healey and Representative Lori Trahan to celebrate at the facility in an industrial ...
American College of Cardiology

Using Her Voice Scholars Program

Women have historically been underrepresented in academic medicine, particularly in tenured and leadership roles. To address this gap, the Academic Cardiology Member Section's Women in Academic ...
BioSpace

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, Aug. 05, 2025 ...
BioSpace

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio ...
Seeking Alpha

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio ...
Nasdaq

Recursion Acquires Full Ownership of ENPP1 Inhibitor Program REV102 from Rallybio for ...

Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...
Nasdaq

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...